Hillstone Networks Acknowledged as an XDR Leader in Frost Radar™ 2023 Report
Hillstone Networks, a leading provider of cybersecurity solutions, has been named an innovation and growth leader in the 2023 Frost Radar™ Extended Detection and Response Report.
The Frost Radar™ 2023 Report is a market analysis conducted by Frost & Sullivan, evaluating industry participants based on their growth strategy, innovation, customer experience, and market share. The report aims to assist organizations in making informed decisions when selecting a reliable XDR solution provider.
“Our inclusion as a leader in the Frost Radar™ 2023 Report reaffirms our dedication to deliver cutting-edge solutions that effectively counter evolving digital threats,” states Tim Liu, CTO and Co-founder at Hillstone Networks. “Our solution integrates advanced threat detection, incident response, and forensic capabilities into a unified platform, empowering businesses to proactively safeguard their digital assets.”
According to Frost & Sullivan, XDR solutions have seen rapid expansion across geographies, industries, and companies of all sizes as it delivers the visibility, integration, analytics, flexibility, and automation that customers need in today’s complex IT environments. Frost states that XDR has three core promises: cross-layered detection and response, meaningful automation, and integration with the security stack.
"Hillstone Networks shows commitment to the Open XDR approach, as it is investing its significant R&D budget in increasing third-party integrations and providing software development kits (SDKs) to facilitate integration with its platform,” states Lucas Ferreyra, Industry Analyst at Frost & Sullivan. “Hillstone Networks has developed a compelling growth strategy, that involves leveraging the increasing relevance of managed security to allow MSSPs to use its XDR solution, broadening its reach while targeting high-growth sectors such as government, healthcare, education, and manufacturing. Such understanding of the market will allow Hillstone Networks to unlock further growth opportunities in the extremely competitive market of XDR.”
Hillstone’s commitment to continuous innovation and successful customer deployments contributes to its emergence as a frontrunner in the XDR domain, as well as delivering on the core promises of XDR:
- Hillstone’s AI-powered threat detection and response capabilities can find and mitigate attacks before they have a chance to exploit the most vital asset in the enterprise – data. The Hillstone XDR solution uses advanced machine learning (ML) algorithms through unknown malware and abnormal detection, advanced threat correlation analytics, and automatic threat mitigation.
- Hillstone XDR also includes automated orchestration and response. If a remediation strategy has been configured, once a threat is identified, Hillstone XDR will automatically execute the appropriate mitigation actions according to a predefined playbook.
- It includes integration with a wide variety of data across the full spectrum of the network, from endpoints to cloud. This data can include NetFlow, Sysmon, Syslogs, metadata, threat information and third-party logs, all of which are then standardized, correlated, and analyzed to provide complete visibility and break down security information silos. It not only brings full security visibility with far fewer blind spots, but also improves detection accuracy by minimizing false positives.
Learn more about Hillstone XDR here.
About Hillstone Networks
Hillstone Networks is a leader in cybersecurity, delivering both depth and breadth of protection to companies of all sizes, from edge to cloud, and across any workload. Hillstone Networks’ Integrative Cyber Security approach brings coverage, control, and consolidation to more than 26,000 enterprises worldwide. www.hillstonenet.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230912650308/en/
Contact information
Zeyao Hu
+1 4085086750
inquiry@hillstonenet.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
